Invus Financial Advisors’s NovoCure NVCR Stock Holding History

Invus Financial Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$6.01M	Hold	350,884	–	–	6.74%	6
2024 Q1	$5.48M	Hold	350,884	–	–	4.36%	6
2023 Q4	$5.24M	Hold	350,884	–	–	4.1%	7
2023 Q3	$5.67M	Hold	350,884	–	–	3.55%	7
2023 Q2	$14.6M	Hold	350,884	–	–	7.79%	5
2023 Q1	$21.1M	Hold	350,884	–	–	13.74%	5
2022 Q4	$25.7M	Hold	350,884	–	–	13.69%	4
2022 Q3	$26.7M	Hold	350,884	–	–	14.63%	3
2022 Q2	$24.4M	Hold	350,884	–	–	14.72%	3
2022 Q1	$29.1M	Hold	350,884	–	–	12.93%	5
2021 Q4	$26.3M	Hold	350,884	–	–	8.01%	5
2021 Q3	$40.8M	Hold	350,884	–	–	10.92%	4
2021 Q2	$77.8M	Hold	350,884	–	–	15.51%	3
2021 Q1	$46.4M	Hold	350,884	–	–	10.63%	4
2020 Q4	$60.7M	Hold	350,884	–	–	25.38%	1
2020 Q3	$39.1M	Sell	350,884 -120,000	-25%	-$9.6M	18.79%	3
2020 Q2	$27.9M	Hold	470,884	–	–	10.09%	5
2020 Q1	$31.7M	Hold	470,884	–	–	15.57%	3
2019 Q4	$39.7M	Buy	+470,884	New	+$38M	20.13%	3

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invus Financial Advisors's NVCR Position: Q2 2024 in Review

Invus Financial Advisors held its NovoCure (NVCR) position steady in Q2 2024 at 350,884 shares worth $6.01M. The position accounts for 6.74% of the portfolio, ranked #6.

Invus Financial Advisors first reported a position in NVCR in Q4 2019 and has held it in 19 quarters since. The position peaked at $77.8M in Q2 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

Invus Financial Advisors held 350,884 shares of NovoCure worth $6.01M as of Q2 2024.
Invus Financial Advisors left its NovoCure share count unchanged in Q2 2024.
NovoCure made up 6.74% of Invus Financial Advisors's portfolio in Q2 2024, its #6 holding.
Invus Financial Advisors first reported a position in NovoCure in Q4 2019 and has held it in 19 quarters since.
Invus Financial Advisors's NovoCure position peaked at $77.8M in Q2 2021.
237 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Invus Financial Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.